Evidence map›Paper›PMID 28916879›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2018

A score combining baseline neutrophilia and primary tumor SUV

Antoine Schernberg, Sylvain Reuze, Fanny Orlhac, Irène Buvat, Laurent Dercle, Roger Sun, Elaine Limkin, Alexandre Escande, Christine Haie-Meder, Eric Deutsch and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Systematic review of artificial intelligence in brachytherapy.Journal of contemporary brachytherapy · 2026
    Review
  3. Article
  4. Review
  5. [Diagnostics (Basel, Switzerland) · 2024
    Review
  6. Article
  7. Improved Prognosis of Treatment Failure in Cervical Cancer with Nontumor PET/CT Radiomics.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  8. Article
  9. Article
  10. Standardized Uptake Value forClinical cancer research : an official journal of the American Association for Cancer Research · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Evaluating FocalNuclear medicine and molecular imaging · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Antoine SchernbergRadiation Oncology Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, F-94805, Villejuif, France.
Sylvain ReuzeRadiation Oncology Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, F-94805, Villejuif, France.
Fanny OrlhacINSERM, U1030, F-94805, Villejuif, France.
Irène BuvatIMIV, CEA, Inserm, CNRS, Univ. Paris-Sud, Université Paris-Saclay, CEA-SHFJ, Orsay, France.
Laurent DercleDepartment of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France.
Roger SunRadiation Oncology Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, F-94805, Villejuif, France.
Elaine LimkinINSERM, U1030, F-94805, Villejuif, France.
Alexandre EscandeRadiation Oncology Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, F-94805, Villejuif, France.
Christine Haie-MederRadiation Oncology Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, F-94805, Villejuif, France.
Eric DeutschRadiation Oncology Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, F-94805, Villejuif, France.
Cyrus ChargariRadiation Oncology Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, F-94805, Villejuif, France.
Charlotte RobertRadiation Oncology Department, Gustave Roussy Cancer Campus, 114 rue Edouard Vaillant, F-94805, Villejuif, France. ch.robert@gustaveroussy.fr.ORCID http://orcid.org/0000-0001-8838-1343

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe investigated whether a score combining baseline neutrophilia and a PET biomarker could predict outcome in patients with locally advanced cervical cancer (LACC).

methodsPatients homogeneously treated with definitive chemoradiation plus image-guided adaptive brachytherapy (IGABT) between 2006 and 2013 were analyzed retrospectively. We divided patients into two groups depending on the PET device used: a training set (TS) and a validation set (VS). Primary tumors were semi-automatically delineated on PET images, and 11 radiomics features were calculated (LIFEx software). A PET radiomic index was selected using the time-dependent area under the curve (td-AUC) for 3-year local control (LC). We defined the neutrophil SUV grade (NSG = 0, 1 or 2) score as the number of risk factors among (i) neutrophilia (neutrophil count >7 G/L) and (ii) high risk defined from the PET radiomic index. The NSG prognostic value was evaluated for LC and overall survival (OS).

resultsData from 108 patients were analyzed. Estimated 3-year LC was 72% in the TS (n = 69) and 65% in the VS (n = 39). In the TS, SUV

conclusionThis innovative scoring approach combining baseline neutrophilia and a PET biomarker provides an independent prognostic factor to consider for further clinical investigations.

Indexed as

Positron-Emission TomographyAdultAgedAged, 80 and overBiological TransportBrachytherapyChemoradiotherapyFemaleFluorodeoxyglucose F18HumansImage Processing, Computer-AssistedMiddle AgedNeoplasm GradingNeutrophilsPrognosisRetrospective StudiesFluorodeoxyglucose F18BiomarkersBrachytherapyCervical carcinomaNeutrophiliaPrognostic factorRadiomics

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.